Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 14/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599859 | 1.00 | GPR183 (0.66) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16599936 | 0.89 | GPR183 (0.73) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16599938 | 0.89 | GPR183 (0.73) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16600409 | 0.89 | GPR183 (0.77) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16600407 | 0.89 | GPR183 (0.77) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16614487 | 0.89 | GPR183 (0.77) | GPR183NPC1RAB9ATDP1 | |
| SCHEMBL20684457 | 0.85 | GPR183 (0.78) | GPR183SMN1; SMN2 | |
| SCHEMBL16599931 | 0.84 | GPR183 (0.73) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16599928 | 0.84 | GPR183 (0.73) | GPR183NPC1RAB9ATDP1ENPP2 | |
| SCHEMBL16600071 | 0.81 | GPR183 (0.78) | GPR183SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196369-B2 | Spirocyclic EBI2 modulators | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-05 | — | — | US | claimed |
| WO-2015048567-A1 | SPIROCYCLIC EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196369-B2 | Spirocyclic EBI2 modulators | HAVCR2, BIRC2, ESR2 | GPR183 17/4885NPC1 1288/4885RAB9A 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.